


Claims:

1. A pharmaceutical composition, comprising: a compound of formula (1) in solid form:




(1)

together with a pharmaceutically acceptable carrier or excipient,

provided that the compound of formula (1) is present in polymorphic Form A and is substantially free of other polymorphic forms.

2. The composition of claim 1 in which the compound of formula (1) is present as orthorhombic crystals.
3. The composition of claim 1, which is in the form of a tablet or capsule.
4. The tablet or capsule of claim 3, which gives rise to a PXRD pattern substantially as shown for polymorphic Form A in Figure 6.
5. The composition of claim 1, wherein at least about 90% of the compound of formula (1) is polymorphic Form A, as defined by PXRD peak heights around 9° 2-theta.
6. The composition of claim 1, further comprising lactose and microcrystalline cellulose.
7. The tablet of claim 3, which weighs between 250 and 500 mg.
8. A composition comprising isolated crystals of the compound of formula (1)



(1)

in which the isolated crystals of compound (1) are present in polymorphic Form A and substantially free of other polymorphs.

9. The composition of claim 8, wherein the isolated crystals of compound (1) are present as orthorhombic crystals.

10. The composition of claim 8, wherein the isolated crystals of compound (1) exhibit a PXRD pattern substantially as shown for polymorphic Form A in Figure 6.

11. The composition of claim 8, wherein the isolated crystals are at least about 90% polymorphic Form A, as defined by PXRD peak heights around 9° 2-theta.

12. The composition of claim 8, wherein the isolated crystals of compound (1) contain at least about 90% of polymorphic Form A with respect to other polymorphic forms.